These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 7645240)

  • 21. Effect of preexisting anti-herpes immunity on the efficacy of herpes simplex viral therapy in a murine intraperitoneal tumor model.
    Lambright ES; Kang EH; Force S; Lanuti M; Caparrelli D; Kaiser LR; Albelda SM; Molnar-Kimber KL
    Mol Ther; 2000 Oct; 2(4):387-93. PubMed ID: 11020355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new mouse model of experimental melanoma for vaccine and lymphokine therapy.
    Shrayer DP; Bogaars H; Wolf SF; Hearing VJ; Wanebo HJ
    Int J Oncol; 1998 Aug; 13(2):361-74. PubMed ID: 9664134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment.
    Qiao J; Moreno J; Sanchez-Perez L; Kottke T; Thompson J; Caruso M; Diaz RM; Vile R
    Gene Ther; 2006 Oct; 13(20):1457-70. PubMed ID: 16724095
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF 10.
    Teshigahara O; Goshima F; Takao K; Kohno S; Kimata H; Nakao A; Nishiyama Y
    J Surg Oncol; 2004 Jan; 85(1):42-7. PubMed ID: 14696086
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors.
    Sampath P; Hanes J; DiMeco F; Tyler BM; Brat D; Pardoll DM; Brem H
    Cancer Res; 1999 May; 59(9):2107-14. PubMed ID: 10232596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection.
    Da Costa XJ; Morrison LA; Knipe DM
    Virology; 2001 Sep; 288(2):256-63. PubMed ID: 11601897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor.
    Toda M; Martuza RL; Rabkin SD
    Mol Ther; 2000 Oct; 2(4):324-9. PubMed ID: 11020347
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors.
    Todo T; Rabkin SD; Martuza RL
    Cancer Gene Ther; 2000 Jun; 7(6):939-46. PubMed ID: 10880026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An oncolytic adenoviral vector carrying the tyrosinase promoter for glioma gene therapy.
    Ulasov IV; Rivera AA; Nettelbeck DM; Rivera LB; Mathis JM; Sonabend AM; Tyler M; Wang M; Douglas JT; Lesniak MS
    Int J Oncol; 2007 Nov; 31(5):1177-85. PubMed ID: 17912445
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Innate and acquired immunity to herpes simplex virus type 1.
    Halford WP; Veress LA; Gebhardt BM; Carr DJ
    Virology; 1997 Sep; 236(2):328-37. PubMed ID: 9325240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
    Todo T; Martuza RL; Dallman MJ; Rabkin SD
    Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Avian adenovirus vector CELO-TK displays anticancer activity in human cancer cells and suppresses established murine melanoma tumors.
    Shashkova EV; Cherenova LV; Kazansky DB; Doronin K
    Cancer Gene Ther; 2005 Jul; 12(7):617-26. PubMed ID: 15761475
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Gene therapy using recombinant adenovirus carrying herpes simplex-thymidine kinase gene to treat mouse B 16 melanoma in vivo].
    Xu RE; Ying BB; Zhao SY; Li CB
    Shi Yan Sheng Wu Xue Bao; 1997 Sep; 30(3):261-71. PubMed ID: 11039021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncolysis by viral replication and inhibition of angiogenesis by a replication-conditional herpes simplex virus that expresses mouse endostatin.
    Mullen JT; Donahue JM; Chandrasekhar S; Yoon SS; Liu W; Ellis LM; Nakamura H; Kasuya H; Pawlik TM; Tanabe KK
    Cancer; 2004 Aug; 101(4):869-77. PubMed ID: 15305421
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy.
    Velicu S; Han Y; Ulasov I; Brown IE; El Andaloussi A; Gajewski TF; Lesniak MS
    J Neuroimmunol; 2006 May; 174(1-2):74-81. PubMed ID: 16504307
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer.
    Coukos G; Makrigiannakis A; Kang EH; Caparelli D; Benjamin I; Kaiser LR; Rubin SC; Albelda SM; Molnar-Kimber KL
    Clin Cancer Res; 1999 Jun; 5(6):1523-37. PubMed ID: 10389942
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant.
    Randazzo BP; Bhat MG; Kesari S; Fraser NW; Brown SM
    J Invest Dermatol; 1997 Jun; 108(6):933-7. PubMed ID: 9182825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thermotherapy for Harding-Passey melanoma: light and electron microscopic study.
    Vicente V; Gómez M; Gómez S; Calderon F; Canteras M; Cremades A
    Histol Histopathol; 1987 Oct; 2(4):369-81. PubMed ID: 2980740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Karyometrical and cytochemical studies of Harding-Passey melanoma and Horning-Mitchely kidney tumor. I. Karyometrical studies.
    el-Fiky SM; Abdo SE
    Acta Histochem; 1971; 41(1):84-91. PubMed ID: 5004562
    [No Abstract]   [Full Text] [Related]  

  • 40. Rodent models of brain metastasis in melanoma.
    Cranmer LD; Trevor KT; Bandlamuri S; Hersh EM
    Melanoma Res; 2005 Oct; 15(5):325-56. PubMed ID: 16179861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.